{
    "nct_id": "NCT04173273",
    "official_title": "A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease",
    "inclusion_criteria": "* Men or women 18 to 80 years of age,\n* Ability to provide written informed consent or assent and to be compliant with the schedule of protocol assessments\n* Diagnosed with Crohn's disease (CD) ≥ 3 months\n* Have moderately to severely active CD at Screening\n* Demonstrated inadequate response (ie, primary non-response), loss of response to, or intolerance to ≥ 1 of the following therapies for the treatment of CD:\n\n  1. Oral corticosteroids (eg, prednisone or its equivalent, budesonide)\n  2. Immunosuppressants (eg, azathioprine [AZA], 6 mercaptopurine [6-MP], or methotrexate [MTX])\n  3. Tumor necrosis factor alpha (TNFα) antagonists (eg, infliximab, adalimumab, certolizumab pegol, or biosimilars)\n  4. Integrin receptor antagonist (eg, vedolizumab)\n  5. Interleukin -12/-23 antagonist (eg, ustekinumab)\n* Females of childbearing potential must be nonpregnant\n* Females of childbearing potential and males must use contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* History of inadequate response (ie, primary non-response) to agents from ≥ 2 classes of biologics marketed for the treatment of CD (ie, TNFα antagonists, interleukin 12/ 23 antagonist, and integrin receptor antagonist).\n* Have ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, diverticular disease associated colitis, toxic megacolon, or active infectious colitis or test positive for Clostridioides difficile toxin at Screening.\n* Have functional or post-operative short-bowel syndrome or any associated complications that may require surgery or interfere with efficacy assessments\n* Had surgical treatment for intra abdominal abscesses ≤ 8 weeks prior to randomization or surgical treatment for perianal abscesses ≤ 4 weeks prior to randomization.\n* Had intestinal resection ≤ 24 weeks prior to randomization or other intra abdominal surgeries ≤ 12 weeks prior to randomization.\n* Have an ileostomy or a colostomy.\n\nInclusion Criteria for Substudy 3:\n\n- Participants who entered the Extended Induction Period of Substudy 1 and Substudy 2 must have completed the Extended Induction -Week 6 Visit\n\nInclusion Criteria for Substudy 4:\n\n- Participant must have completed the Week 52 Visit of Substudy 3 or the Week 66 Visit of Substudy A",
    "miscellaneous_criteria": "Eligibility criteria applicable to all substudies:"
}